130 related articles for article (PubMed ID: 38325712)
21. Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.
Hossaini Nasr S; Rashidijahanabad Z; Ramadan S; Kauffman N; Parameswaran N; Zinn KR; Qian C; Arora R; Agnew D; Huang X
Nanoscale; 2020 May; 12(17):9541-9556. PubMed ID: 32314997
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic and Dynamic Heterogeneity of Nonlamellar Lyotropic Liquid Crystalline Nanodispersions.
Yaghmur A; Moghimi SM
ACS Nano; 2023 Nov; 17(22):22183-22195. PubMed ID: 37943319
[TBL] [Abstract][Full Text] [Related]
23. Chemistry and Geometry of Counterions Used in Hydrophobic Ion Pairing Control Internal Liquid Crystal Phase Behavior and Thereby Drug Release.
Ristroph K; Salim M; Clulow AJ; Boyd BJ; Prud'homme RK
Mol Pharm; 2021 Apr; 18(4):1666-1676. PubMed ID: 33656349
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability.
Kong R; Zhu X; Meteleva ES; Polyakov NE; Khvostov MV; Baev DS; Tolstikova TG; Dushkin AV; Su W
Drug Deliv Transl Res; 2018 Oct; 8(5):1200-1213. PubMed ID: 30039497
[TBL] [Abstract][Full Text] [Related]
25. Synthetic ionizable aminolipids induce a pH dependent inverse hexagonal to bicontinuous cubic lyotropic liquid crystalline phase transition in monoolein nanoparticles.
Rajesh S; Zhai J; Drummond CJ; Tran N
J Colloid Interface Sci; 2021 May; 589():85-95. PubMed ID: 33450463
[TBL] [Abstract][Full Text] [Related]
26. Cubosomes and Hexosomes as Novel Nanocarriers for Bioactive Compounds.
Tan C; Hosseini SF; Jafari SM
J Agric Food Chem; 2022 Feb; 70(5):1423-1437. PubMed ID: 35089018
[TBL] [Abstract][Full Text] [Related]
27. Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats.
Mahmoud MO; Aboud HM; Hassan AH; Ali AA; Johnston TP
J Control Release; 2017 May; 254():10-22. PubMed ID: 28344015
[TBL] [Abstract][Full Text] [Related]
28. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury.
Yu H; Jin F; Liu D; Shu G; Wang X; Qi J; Sun M; Yang P; Jiang S; Ying X; Du Y
Theranostics; 2020; 10(5):2342-2357. PubMed ID: 32104507
[TBL] [Abstract][Full Text] [Related]
29. Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology.
Sarangi B; Jana U; Sahoo J; Mohanta GP; Manna PK
Biomed Microdevices; 2018 Jun; 20(3):53. PubMed ID: 29946758
[TBL] [Abstract][Full Text] [Related]
30. In situ monitoring of the formation of lipidic non-lamellar liquid crystalline depot formulations in synovial fluid.
Yaghmur A; Rappolt M; Jonassen ALU; Schmitt M; Larsen SW
J Colloid Interface Sci; 2021 Jan; 582(Pt B):773-781. PubMed ID: 32916575
[TBL] [Abstract][Full Text] [Related]
31. Atorvastatin-loaded peptide amphiphiles against corneal neovascularization.
Sánchez-López E; Gómara MJ; Haro I
Nanomedicine (Lond); 2023 Jul; 18(17):1095-1108. PubMed ID: 37610088
[TBL] [Abstract][Full Text] [Related]
32. Formulation and Evaluation of Atorvastatin Calcium-Poly-ε-Caprolactone Nanoparticles Loaded Ocular Inserts for Sustained Release and Antiinflammatory Efficacy.
Girgis GNS
Curr Pharm Biotechnol; 2020; 21(15):1688-1698. PubMed ID: 32427080
[TBL] [Abstract][Full Text] [Related]
33. Visible light-triggered cargo release from donor acceptor Stenhouse adduct (DASA)-doped lyotropic liquid crystalline nanoparticles.
Jia S; Tan A; Hawley A; Graham B; Boyd BJ
J Colloid Interface Sci; 2019 Jul; 548():151-159. PubMed ID: 30991181
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial proanthocyanidin-chitosan composite nanoparticles loaded with gentamicin.
Alfaro-Viquez E; Esquivel-Alvarado D; Madrigal-Carballo S; Krueger CG; Reed JD
Int J Biol Macromol; 2020 Nov; 162():1500-1508. PubMed ID: 32739510
[TBL] [Abstract][Full Text] [Related]
35. Bioimaging Applications of Non-Lamellar Liquid Crystalline Nanoparticles.
Murgia S; Biffi S; Fornasier M; Lippolis V; Picci G; Caltagirone C
J Nanosci Nanotechnol; 2021 May; 21(5):2742-2759. PubMed ID: 33653441
[TBL] [Abstract][Full Text] [Related]
36. Characterization of oil-free and oil-loaded liquid-crystalline particles stabilized by negatively charged stabilizer citrem.
Nilsson C; Edwards K; Eriksson J; Larsen SW; Østergaard J; Larsen C; Urtti A; Yaghmur A
Langmuir; 2012 Aug; 28(32):11755-66. PubMed ID: 22831645
[TBL] [Abstract][Full Text] [Related]
37. Controlling the pH dependent transition between monoolein Fd3m micellar cubosomes and hexosomes using fatty acetate and fatty acid additive mixtures.
Zhai J; Yap SL; Drummond CJ; Tran N
J Colloid Interface Sci; 2022 Feb; 607(Pt 1):848-856. PubMed ID: 34536939
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticle delivery of grape seed-derived proanthocyanidins to airway epithelial cells dampens oxidative stress and inflammation.
Castellani S; Trapani A; Spagnoletta A; di Toma L; Magrone T; Di Gioia S; Mandracchia D; Trapani G; Jirillo E; Conese M
J Transl Med; 2018 May; 16(1):140. PubMed ID: 29792199
[TBL] [Abstract][Full Text] [Related]
39. Liquid crystalline nanoparticles for drug delivery: The role of gradient and block copolymers on the morphology, internal organisation and release profile.
Chountoulesi M; Perinelli DR; Forys A; Bonacucina G; Trzebicka B; Pispas S; Demetzos C
Eur J Pharm Biopharm; 2021 Jan; 158():21-34. PubMed ID: 33098976
[TBL] [Abstract][Full Text] [Related]
40. Development and characterization of self-nanoemulsifying drug delivery systems (SNEDDS) of atorvastatin calcium.
Mantri SK; Pashikanti S; Murthy KV
Curr Drug Deliv; 2012 Mar; 9(2):182-96. PubMed ID: 22283646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
